Blood Cancer Journal

Papers
(The H4-Index of Blood Cancer Journal is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort149
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma143
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study136
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report134
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M118
Disparities in time to treatment with oral antimyeloma medications112
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib110
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity104
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells102
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT99
A multiparametric niche-like drug screening platform in acute myeloid leukemia99
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes95
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study94
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine82
Genomic landscape of hyperleukocytic acute myeloid leukemia79
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma77
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma77
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid75
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes73
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease69
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study66
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients66
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm66
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor66
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency65
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma64
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management64
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma63
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia60
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia57
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review53
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial53
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy50
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression49
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier46
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis46
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma46
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study46
RSK1 dependency in FLT3-ITD acute myeloid leukemia43
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma43
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma43
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review42
Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia42
0.19256901741028